Enovis Corp 2025年季度报告

financial accounting standards provided pursuant to Section 13(a) of the Exchange Act☐Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☑ As of May2, 2025, there were57,123,051shares of the registrant’s common stock, par value $.001 per share, outstanding. See Notes to Condensed Consolidated Financial Statements. Enovis Corporation (the “Company” or “Enovis”) is an innovation-driven medical technology growth company dedicated todeveloping clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. The Companyconducts its business throughtwooperating segments, Prevention & Recovery (“P&R”) and Reconstructive (“Recon”). The P&R segmentprovides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum frominjury prevention to rehabilitation after surgery, injury, or from degenerative disease. The Recon segment provides surgical implant The Condensed Consolidated Financial Statements included in this quarterly report have been prepared by the Company in accordancewith the rules and regulations of the Securities and Exchange Commission (“SEC”) and accounting principles generally accepted in theUnited States of America (“GAAP”) for interim financial statements and reflect, in the opinion of management, all adjustments, whichconsist solely of normal recurring adjustments, necessary to present fairly the Company’s financial position and results of operations as of footnotes included in the Company’s Annual Report on Form 10-K for the year ended December31, 2024 (the “2024 Form 10-K”), filedwith the SEC on February26, 2025. The Company makes certain estimates and assumptions in preparing its Condensed Consolidated Financial Statements in accordancewith GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets andliabilities as of the date of the Condensed Consolidated Financial Statements, and the reported amounts of revenues and expenses for the 2.Recently Issued Accounting Pronouncements updates to the presentation of certain information for the Company’s segment disclosures. See Note 13 “Segment Information” foradditional information regarding the updates made. financial statements. 2025 Acquisitions deferred consideration and estimated contingent consideration.Threeacquisitions are in the Prevention & Recovery segment andtwoarein the Reconstructive segment. The business acquisitions are accounted for under the acquisition method of accounting, and accordingly, the Consolidated FinancialStatements include the financial position and results of operations from the acquisition dates. The Company preliminarily recorded enterprise value of €800million (the “Lima Acquisition”), consisting of (i) approximately €700million in cash consideration, whichincludes the repayment at closing of certain indebtedness of Lima and (ii)1,942,686shares of common stock of Enovis, par value $0.001per share (the “Contingent Acquisition Shares”), based upon a €100million value divided by the30-dayvolume weighted average price ofEnovis common stock as of the close of business on September 21, 2023. The Contingent Acquisition Shares were issuable intwoequaltranches withinsixandtwelve monthsof the acquisition date upon non-occurrence of certain future events, in each case subject to certainadjustments and conditions as provided for in the purchase agreement. The first tranche of Contingent Acquisition Shares was issued to theseller on July 16, 2024 and the second tranche was issued on January 15, 2025. The cash paid for acquisition was $757.7million, net ofacquired cash. Since the acquisition occurred at the beginning of 2024, the results of operations are fully included in both periodspresented, and the purchase accounting was finalized as of December 31, 2024. See Note 5, “Acquisitions” in the Notes to Consolidated As of April4, 2025, the balance of investments held by the Company without readily determinable fair values was $20.4million. Themajority of these investments are carried at cost less impairments, if any, plus adjustments for fair value indicators from observable price accounting and is recorded at the initial investment amount, adjusted each period for the Company’s share of the income or loss. The Company provides orthopedic solutions, including products and services spanning the full continuum of patient care, from injury 4.Revenue (In thousands)Prevention & Recovery:U.S. Bracing & Support$115,086$U.S. Other P&R66,622 Consolidated Balance Sheets is as follows:Three Months Ended April 4, 2025 of PeriodExpense, netDeductions, netnetTranslation(In thousands)Allowance for Credit Losses$24,466$2,263$(636)$110$643 5.Net Income (Loss) Per Share from Continuing OperationsNet income (loss) per share from continuing operations was computed using the treasury stock metho